One of the most trusted medical journals today would be Oncotarget. It is right now the database of all the reliable academic research and information that many people in the world rely on. One of the latest articles that are being published by Oncotarget today would be the Fox 06 Transcriptional Factor in Breast Carcinogenesis. To learn more about the information, you may want to read on.
The Journal Results
It is shown in the report being published that the FOXO transcriptional factors today would be the four members of carcinogenesis in mammals. The FOXO family is also reported to be some of the causes of breast cancer. Right now there’s poor research so far on what these elements are. However, with Oncotarget’s research, there may now be more potential in finding out more about what causes the medical carcinogen issues. It is also shown in the report from ResearchGate that the overexpression of the human FOX06 would result in the likelihood of having breast tumors. The existence of such gene expression would also be responsible in the proliferation of the breast cancer cells in the body. Check the journal at SCImago Journal & Country Rank.
Oncotarget’s Latest Discoveries
One of the most exemplary studies that EurekaAlert is able to pursue today is the one about how researchers in the Oncotarget database is researching for novel therapeutic ways to understand and cure thyroid cancer. In the press release by Oncotarget, it was shown that there is an abundance among researchers and cancer specialists about the ways in which the thyroid cancer symptoms will be decreased and abated. With Oncotarget’s reputation of only providing the best service in the industry, this aim of researching for the best therapies will not be hard to achieve.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/
An interesting part about Oncotarget’s research for the therapeutic ways is the discovery of the PTC genetic hallmark, which is mostly a mutation of the commonly discovered BRAF gene. Patients who present the BRAFV600E mutation has been referred to the doctors so that they can get a drug called vemurafenib, which will help them cope with the mutation. With such therapy, it’s now easier to find ways to get the cause of the cancer and remedy it. Download output styles at Endnote.com